Authors: John H. Eldridge, Michael A. Egan, Demetrius Matassov, Stefan Hamm, Luz Hermida, Tracy Chen, Marc Tremblay, Susan Sciotto-Brown, Rong Xu, Antony Dimitrov, Emily R. Smith, Marc Gurwith, Robert T. Chen
Year: 2021
Journal: Vaccine
DOI: 10.xxxx/xxxxx or null
Summary#
A protein vaccine for Nipah and Hendra viruses is under clinical evaluation in a Phase 1 study. The paper discusses the standardized template to describe key considerations for the benefit-risk assessment of this type of vaccine.
Key Findings#
- The vaccine employs recombinant soluble Hendra glycoprotein (HeV-sG) adjuvanted with aluminum phosphate.
- The vaccine is under clinical evaluation in a Phase 1 study.
Methodology#
- Study Type: Review
Topics#
Vaccine, Protein, Safety, Benefit/Risk, Nipah, Hendra
Relevance#
The paper discusses a standardized template to assess potential safety issues and understand the benefit-risk of protein vaccines, which may help improve public acceptance and communication of licensed protein vaccines.